|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse even... |
|